Scholarlink

<p>Breast cancer diagnosed during pregnancy (PrBC) is a rare occurrence but may become more prevalent as women nowadays tend to postpone childbearing until later in life. Further understanding of how pregnancy affects the tumor microenvironment (TME) is essential. We constructed Tissue Microarrays (TMA) of tumor specimens from 126 pregnant breast cancer (BC) patients and examined standard BC markers such as ER, PR, Ki67, HER2, tumor infiltrating lymphocytes (TILs), and immunomarkers HLA class I, HLA-G, PD-L1, TIGIT and Nectin-4. Subsequently, we compared our findings with those from a matched non-pregnant cohort of young BC patients. Pregnant BC patients were younger, had significantly higher proliferation rates and a higher expression of Nectin-4. Higher pregnancy related estrogen levels may boost proliferation und Nectin-4 overexpression, promoting BC progression. No further evidence supporting impaired maternal anti-tumor response in BC was observed in this study.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effects of pregnancy on breast cancer immunology: immune biomarker and TIL quantification

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月14日

查看全文
  • Kristin Galas,
  • Moritz Gleitsmann,
  • Julia Rey,
  • Christine Solbach,
  • Isabell Witzel,
  • Thomas Karn,
  • Sabine Schmatloch,
  • Christian Schem,
  • Andreas Schneeweis,
  • Bruno Sinn,
  • Tanja Fehm,
  • Carsten Denkert,
  • Peter Fasching,
  • Anne-Sophie Litmeyer,
  • Frederik Marmé,
  • Paul Jank,
  • Volkmar Müller,
  • Sabine Seiler,
  • Elmar Stickeler,
  • Olaf Ortmann,
  • Marion van Mackelenbergh,
  • Valentina Nekljudova,
  • Johannes Holtschmidt,
  • Sibylle Loibl

摘要

Breast cancer diagnosed during pregnancy (PrBC) is a rare occurrence but may become more prevalent as women nowadays tend to postpone childbearing until later in life. Further understanding of how pregnancy affects the tumor microenvironment (TME) is essential. We constructed Tissue Microarrays (TMA) of tumor specimens from 126 pregnant breast cancer (BC) patients and examined standard BC markers such as ER, PR, Ki67, HER2, tumor infiltrating lymphocytes (TILs), and immunomarkers HLA class I, HLA-G, PD-L1, TIGIT and Nectin-4. Subsequently, we compared our findings with those from a matched non-pregnant cohort of young BC patients. Pregnant BC patients were younger, had significantly higher proliferation rates and a higher expression of Nectin-4. Higher pregnancy related estrogen levels may boost proliferation und Nectin-4 overexpression, promoting BC progression. No further evidence supporting impaired maternal anti-tumor response in BC was observed in this study.